Literature DB >> 31868032

Versatile cationic liposomes for RIP3 overexpression in colon cancer therapy and RIP3 downregulation in acute pancreatitis therapy.

Lijing Zhang1,2, Simeng Liu1, Huimin Liu1, Chengli Yang1, Ailing Jiang1, Heng Wei1, Dan Sun1, Zheng Cai3, Yu Zheng1.   

Abstract

Because the induction of strong host antitumor responses plays a very important role in antitumor therapy, identifying effective approaches to elicit immunogenic cell death could have important implications. RIP3-dependent necroptotic cancer cells have been reported to release damage-associated molecular patterns and enhance antitumor immunity. In this study, hyaluronic acid-conjugated cationic liposomes (DOTAP/DOPE/PEG-DSPE/CHOL) (HA-P-LP) were prepared as a vector for mRIP3-pDNA overexpression in tumours. Compared with standard cationic liposomes, this vector markedly increased cellular gene internalisation in vitro, enhanced the tumour-targeting effect in vivo and exhibited a significant antitumor effect in combination with adjuvant chloroquine. Considering the dramatic increase in RIP3 under the pathological condition of pancreatitis and the correlation between pancreatitis and necroptosis, non-HA-conjugated liposomes with the same formulation loaded with shRNA mRIP3-pDNA effectively controlled the disease by decreasing the serum amylase concentration and inflammatory cell infiltration. The versatile cationic liposomes loaded with plasmids with opposing functions in this study provide a new concept and method for both tumour therapy and pancreatitis therapy.

Entities:  

Keywords:  HA-P-LP; RIP3 downregulation; RIP3 overexpression; necroptosis; pancreatitis

Year:  2020        PMID: 31868032     DOI: 10.1080/1061186X.2019.1708370

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  3 in total

Review 1.  Understanding Necroptosis in Pancreatic Diseases.

Authors:  Ru He; Zhengfeng Wang; Shi Dong; Zhou Chen; Wence Zhou
Journal:  Biomolecules       Date:  2022-06-13

Review 2.  Non-Canonical Programmed Cell Death in Colon Cancer.

Authors:  Bingchen Pan; Bowen Zheng; Chengzhong Xing; Jingwei Liu
Journal:  Cancers (Basel)       Date:  2022-07-07       Impact factor: 6.575

Review 3.  Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine.

Authors:  Xuan Wang; Peng Hua; Chengwei He; Meiwan Chen
Journal:  Acta Pharm Sin B       Date:  2022-04-01       Impact factor: 14.903

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.